---
title: "Tempest Therapeutics 10-K: Net loss $26.3M, EPS $(6.33)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281023009.md"
description: "Tempest Therapeutics reported a net loss of $26.3 million for the year, or $(6.33) per share, reflecting a 37% improvement versus 2024 due to R&D reprioritization and cost reductions. The company had no product revenue and an operating loss of $26.6 million, with an accumulated deficit of $233.4 million. The pipeline was expanded with a dual-targeting CAR-T portfolio, and clinical progress includes Amezalpat Phase 2 completion. The company is focusing on reducing R&D spending and has entered a funding commitment to support development."
datetime: "2026-03-30T12:45:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281023009.md)
  - [en](https://longbridge.com/en/news/281023009.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281023009.md)
---

# Tempest Therapeutics 10-K: Net loss $26.3M, EPS $(6.33)

Tempest Therapeutics reported a net loss of $26.3 million for the year, or $(6.33) per share, reflecting a 37% improvement versus 2024 driven by R&D reprioritization and cost reductions. The company had no product revenue and reported operating loss of $26.6 million. Accumulated deficit stood at $233.4 million.

**Financial Highlights**

-   **Operating loss**: $(26.6) million, decreased 37% versus 2024 due to R&D reprioritization and cost reductions.
-   **Net loss**: $(26.3) million, decreased 37% versus 2024; accumulated deficit $233.4 million.
-   **Net loss per share**: $(6.33), basic and diluted (weighted-average shares 4.15 million).
-   **Revenue**: Not reported; no product revenue (no products approved for commercial sale).

**Business Highlights**

-   **Pipeline expansion**: Acquired a dual-targeting CAR-T portfolio (BCMA/CD19, CD70) and related assets, adding both autologous and allogeneic candidates to the pipeline.
-   **Clinical progress & plans**: Amezalpat Phase 2 complete and positioned as Phase 3–ready in hepatocellular carcinoma (HCC); TPST-1495 Phase 2 for FAP planned with NCI funding in 2026.
-   **Operational shift & cost focus**: Reduced R&D spending and workforce in 2025 while prioritizing strategic alternatives and conserving cash to extend runway.
-   **Funding & development strategy**: Entered a funding commitment and completed a private placement to support near-term development and ongoing business development discussions.

Original SEC Filing: Tempest Therapeutics, Inc. \[ TPST \] - 10-K - Mar. 30, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [TPST.US](https://longbridge.com/en/quote/TPST.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Vertex Says Health Canada Accepts Suzetrigine Application for Review](https://longbridge.com/en/news/287257602.md)
- [Nuvalent to present pivotal ALKOVE-1 neladalkib data in ALK-positive NSCLC at ASCO 2026](https://longbridge.com/en/news/287275055.md)
- [Black Diamond reports Phase 2 silevertinib mPFS 15.2 months in frontline EGFR-mutant NSCLC](https://longbridge.com/en/news/287274011.md)
- [Cardiff Oncology updates Phase 2 onvansertib data in first-line RAS-mutated mCRC trial](https://longbridge.com/en/news/287272648.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)